Business
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-106 for the Treatment of Angelman Syndrome
Virtual event on Tuesday, October 26, 2021, at 10:00 a.m. ET will provide an overview of Angelman syndrome, natural history data, gene therapy treatment
About this update from Taysha Gene Therapies, Inc.
[{"type":"text","content":"\nVirtual event on Tuesday, October 26, 2021, at 10:00 a.m. ET will provide an overview of Angelman syndrome, natural history data, gene therapy treatment mechanisms and Taysha’s clinical development strategy\n\n DALLAS--(BUSINESS WIRE)--\nTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced it will host a virtual key opinion leader (KOL) webinar on TSHA-106 for the treatment of Angelman syndrome on Tuesday, October 26, 2021, from 10:00 a.m. to 1:00 p.m. ET.\n\nThe event will feature a presentation from KOL Ben Philpot, Ph.D., Associate Director of the UNC Neuroscience Center at UNC-Chapel Hill, who will discuss the gene replacement approach to treating patients with Angelman syndrome, a genetic condition that affects the nervous system and causes severe physical and learning disabilities.\n\nThe event will also feature presentations from:\n\n\nKimberly Goodspeed, M.D., Assistant Professor in the Departments of Pediatrics, Neurology, and Psychology at UT Southwestern, who will provide an overview of Angelman syndrome\n\n\n\nAllyson Berent DVM, Dipl. ACVIM, Chief Science Officer for the Foundation for Angelman Therapeutics, Director of the Angelman Syndrome Biomarker and Outcome Measure Consortium and Co-Director of the International Angelman Syndrome Research Council, who will discuss the natural history of the disease and the burden of disease as well as provide a patient and caregiver perspective\n\n\n\nRyan Butler, Ph.D., Assistant Professor in the Department of Psychiatry and Pediatrics at UT Southwestern, who will discuss the vectorized knockdown of UBE3A-ATS approach to treating Angelman syndrome\n\n\n\nSuyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Chief Medical Officer and Head of R&D of Taysha, who will review the clinical development strategy for the treatment of Angelman syndrome\n\n\nTo register for the investor day, please click here. A live video webcast will be available in the \"Events & Media\" section of the Taysha corporate website. An archived version of the event will be available on the website for 60 days.\n\nAbout Taysha Gene Therapies\n\nTaysha Gene Therapies ...